Search This Blog

Wednesday, August 5, 2026

New Amsterdam Pharma sets PREVAIL cardiovascular interim analysis for 4Q 2026

 

NewAmsterdam Pharma reports Q2 2026 results with $64.1 million net loss, $678.3 million cash, sets PREVAIL cardiovascular interim analysis for 4Q 2026

  • PREVAIL cardiovascular outcomes interim analysis results expected in 1Q 2027 following the planned 4Q 2026 analysis.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)